Wei-Wu He and Tak Mak join EntreMed board
This article was originally published in Scrip
EntreMed, a clinical-stage pharmaceutical company developing cancer therapeutics, has appointed Dr Wei-Wu He executive chair, and Dr Tak Mak a member of the board of directors. Dr He is currently CEO and chair of OriGene Technologies, and is the founder and general partner of Emerging Technology Partners. Dr Mak is director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a professor in the departments of medical biophysics and immunology at the University of Toronto. He is also an officer of the Order of Canada, and a foreign associate of the National Academy of Sciences. He is best known as the leading scientist of the group that first cloned the genes of the human T cell antigen receptor.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.